The FDA was busy in April 2024, making a number of decisions on potential new therapeutic agents including granting approvals, a clearance, and a fast track designation, issuing a...

WATCH TIME: 5 minutes'What I really wanted to highlight is that we should be thinking about equity, and access. Many solutions might have the ability to increase clinician efficien...

Claire Henchcliffe, MD(Credit: Weill Cornell Medicine)According to a recent report from GlobalData, using data from BlueRock Therapeutics’ phase 1 study (NTC04802733) assessing be...

WATCH TIME: 4 minutes'I think what gene therapy provides us is a new opportunity to really target the specific problem of the disease at its core.'AB-1005 (AskBio), an investigatio...

Chronic demyelinating polyneuropathy (CIDP) is a neuromuscular disorder characterized by progressive weakness and impaired sensory function in the arms and legs. It is an autoimmun...

Newly announced preliminary top-line results from a planned interim analysis of a phase 2 study (NCT04845178) showed that treatment with ABP-450 (AEON Biopharma) did not meet its p...

Helen Colquhoun, MD(Credit: LinkedIn)Recently published in Movement Disorders, results from the double-blind, randomized, placebo-controlled, phase 2 KINETIC trial (NCT04305275) as...

Parasomnias are sleep disorders that involve abnormal behaviors, emotional experiences, perceptions, and dream activity, occurring during specific sleep stages or sleep-wake transi...

WATCH TIME: 6 minutes'It's important because when patients finally seek treatment for agitation and aggression that’s been going on for quite a while and has gotten to a critical ...

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and...